ASCO Annual Meeting

Real-world data showed zanubrutinib was associated with longer time to next treatment and improved overall survival vs acalabrutinib in treatment-naive CLL.

Elena Elimova, MD, discusses data from a HERIZON-GEA-01 PD-L1 subgroup analysis in HER2-positive gastroesophageal adenocarcinoma.

Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.

Oncology experts provide commentary on the meeting's biggest and most impactful presentations across the GI cancer continuum.

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Experts highlight some of the top hematologic oncology data presented at ASCO 2026, including key studies in multiple myeloma and diffuse large B-cell lymphoma.

Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.

First-line zanubrutinib improved real-world treatment duration, time to next treatment, and survival in older chronic lymphocytic leukemia.

Varegacestat reduced the risk of disease progression or death by 84% vs placebo in progressing desmoid tumors.

Dato-DXd led to benefits in terms of TFST, PFS2, and TSST vs chemotherapy in frontline TNBC.

Post-surgery ctDNA status was prognostic for distant recurrence in early TNBC, and the prognostic value of ctDNA status per WGS outperformed pCR status.

Sintilimab plus adjuvant capecitabine did not improve 2-year PFS outcomes vs capecitabine alone in NPC with suboptimal response to induction chemotherapy.

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

Selinexor plus ruxolitinib produced higher SVR35 rates than ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.

John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

A switch to camizestrant upon emergence of an ESR1 mutation improved PFS2 in ER-positive, HER2-negative advanced breast cancer.

Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

Sacituzumab govitecan plus pembrolizumab improved PFS2 and delayed subsequent therapy vs chemo/pembrolizumab in PD-L1+ mTNBC.

Pemigatinib improved PFS as first-line therapy for FGFR2-rearranged cholangiocarcinoma in the phase 3 FIGHT-302 trial.

Prespecified biomarker analyses of ASCENT-03 and ASCENT-04 showed longer PFS with sacituzumab govitecan–based regimens vs comparators in TNBC.

Rilvegostomig plus T-DXd yielded high pCR rates in immune-positive HER2-negative breast cancer.

Frontline darovasertib plus crizotinib improved PFS vs investigator’s choice of therapy in patients with HLA-A*02:01–negative metastatic uveal melanoma.

Linda R. Mileshkin, MBBS, FRACP, Mbioeth, highlights efficacy data with puxitatug samrotecan in patients with ovarian and endometrial cancers.

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.